Publication at Third Faculty of Medicine |
2022
Abstract
Systemic therapy is the standard of care for patients with metastatic hormone-sensitive prostate cancer. However, recent results from studies show that radiation therapy can further improve cancer outcomes in some patients.
It is the irradiation of the primary tumor, i.e. the prostate, as well as the irradiation of metastases. In a subset of patients with low-volume prostate disease, radiation improves overall survival.
In oligometastatic disease, irradiation of metastases improves progression-free survival and also delays the time to onset of androgen deprivation. Radiation therapy thus becomes part of a comprehensive treatment for metastatic hormone-sensitive prostate cancer.